ReviewBlood cancer journal2021
Comprehensive Review of AL amyloidosis: some practical recommendations.
Review in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Prognostic factors in Chinese patients with immunoglobulin light chain amyloidosis: a scoping review and meta-analysis.Annals of medicine · 2024Pooled it
- Global epidemiology of amyloid light-chain amyloidosis.Orphanet journal of rare diseases · 2022Pooled it
- Delayed kidney response in AL amyloidosis: prevalence and clinical significance.Clinical kidney journal · 2026Article
- Article
- Hypercoagulability in Light Chain Amyloidosis and the Importance of Predictive Value of TEG and TGT for Thrombosis Recurrence in Inflammatory States.Diagnostics (Basel, Switzerland) · 2026Article
- 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2026Review
- Association Between Common Variable Immunodeficiency and Pulmonary Amyloidosis: Review.Journal of clinical medicine · 2026Review
- Physiologically relevant forms of Tc- and Re-pyrophosphate radioactive tracers and the basis of their transthyretin amyloid sensitivity.Scientific reports · 2026Article
- Economic Burden of Overall and Advanced Light Chain Amyloidosis: Results from a Claims Linked Electronic Health Record Database Analysis.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Reduced heart rate variability is associated with disease severity in AL amyloidosis: a retrospective cohort study.Frontiers in medicine · 2026Article
- Clinical significance of t(11;14) translocation in systemic AL amyloidosis in the era of daratumumab therapy.Clinical and experimental medicine · 2025Article
- A Case of AL Amyloidosis With Hepatomegaly as the Main Clinical Manifestation.Clinical case reports · 2025Article
- Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.Haematologica · 2025Article
- Transthyretin Amyloidosis-One of the Causes of Heart Failure in Patients with Severe Clinical Course of COVID-19.International journal of molecular sciences · 2025Article
- What Cardiologists Should Know About Amyloidosis.Journal of clinical medicine · 2025Review
- Simultaneous onset of systemic sclerosis and light chain amyloidosis: the first report of a case report and review of the literature.Rheumatology international · 2025Review
- Emerging Insights into Granulomatous and Amyloidogenic Cardiomyopathies.Journal of clinical medicine · 2025Review
- Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study.Blood advances · 2025Article
- Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims database.Open heart · 2025Article
- Integrated specialty care for amyloidosis: a scoping review using the Consolidated Framework for Implementation Research.BMC health services research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (FLC) that infiltrate peripheral tissues and result in detrimental end-organ damage. Disease presentation is rather vague, and the hallmark of treatment is early diagnosis before irreversible end-organ damage. Once diagnosed, treatment decision is transplant-driven whereby ~20% of patients are eligible for autologous stem cell transplantation (ASCT) with or without bortezomib-based induction. In the setting of ASCT-ineligibility, bortezomib plays a central role in upfront treatment with the recent addition of daratumumab to the current emerging standard of care. In general, management of AL amyloidosis is aimed at achieving deep, durable responses with very close monitoring for early detection of relapse/refractory disease. This article provides a comprehensive review of the management of patients with AL amyloidosis including goals of therapy, current treatment guidelines in the setting of both ASCT-eligibility and ineligibility, treatment response monitoring recommendations, toxicity management, and treatment of relapse/refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.